CClinicalTrials.gg
WithdrawnNCT06289153Updated Jan 9, 2026

Internal Bracing Following ACL Reconstruction

An interventional study of Arthrex Internal Brace and ACL Reconstruction in ACL Injury, sponsored by NYU Langone Health. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Study not initiated.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess Anterior Cruciate Ligament (ACL) healing through analyzing clinical, radiographic, functional and patient-reported outcomes following ACL reconstruction with quadriceps graft with and without internal bracing.

Read the detailed description

The primary objective is to compare functional outcomes at one year in patients who underwent ACLR with or without internal bracing. The secondary outcomes are to characterize the evidence of ACL healing at 1 year by MRI imaging of the knee and obtain data on clinical and patient reported outcomes at 1 year follow-up.

02

Conditions studied

  • ACL Injury
03

In context

Anterior Cruciate Ligament Injuries

512 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 163 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • History of ACL injury indicated for isolated reconstruction, without concomitant ligament reconstruction or repair, cartilage repair procedure, or osteotomy.

Exclusion criteria

Exclusion Criteria:

  • Patients who underwent concomitant ligament reconstruction or repair, cartilage repair procedure, or osteotomy.
  • History of blood-borne diseases including HIV, HBV, HCV, HTLV, and syphilis.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Internal Brace

    Patients will undergo ACL Reconstruction (ACLR) with an internal brace. At 6 months post-operation patients will fill out clinical outcome surveys. At the routine 1 year postoperative visit, all patients will fill out clinical outcome surveys and undergo MRI evaluation of the knee.

    Device: Arthrex Internal Brace · Procedure: ACL Reconstruction

  • Active comparator
    Standard ACLR

    Patients will undergo ACLR without an internal brace. At 6 months post-operation patients will fill out clinical outcome surveys. At the routine 1 year postoperative visit, all patients will fill out clinical outcome surveys and undergo MRI evaluation of the knee.

    Procedure: ACL Reconstruction

Interventions

  • DeviceArthrex Internal Brace

    The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.

  • ProcedureACL Reconstruction

    All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in 2000 International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form at Month 6 Post-Operation

    The IKDC is a patient-completed tool assessing knee symptoms (7 items), function (2 items), and sports activities (2 items). Scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).

    Time frame: Baseline, Month 6 Post-Operation

  2. Change from Baseline in 2000 IKDC Subjective Knee Evaluation Form Score at Month 12 Post-Operation

    The IKDC is a patient-completed tool assessing knee symptoms (7 items), function (2 items), and sports activities (2 items). Scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).

    Time frame: Baseline, Month 12 Post-Operation

  3. Change from Baseline in Lysholm Knee Scoring System Score at Month 6 Post-Operation

    The Lysholm Knee Scoring System is an 8-item assessment of the prevalence of knee problems. The total score ranges from 0-100; scores between 95 and 100 are regarded as exceptional, 84 and 94 as acceptable, 65 to 83 as fair, and less than 65 as poor.

    Time frame: Baseline, Month 6 Post-Operation

  4. Change from Baseline in Lysholm Knee Scoring System Score at Month 12 Post-Operation

    The Lysholm Knee Scoring System is an 8-item assessment of the prevalence of knee problems. The total score ranges from 0-100; scores between 95 and 100 are regarded as exceptional, 84 and 94 as acceptable, 65 to 83 as fair, and less than 65 as poor.

    Time frame: Baseline, Month 12 Post-Operation

  5. Change from Baseline in Visual Analogue Scale (VAS) - Pain Score at Month 6 Post-Operation

    Participants rate their pain on a scale from 0 (no pain) to 10 (worst pain imaginable); the response is the total score.

    Time frame: Baseline, Month 6 Post-Operation

  6. Change from Baseline in Visual Analogue Scale (VAS) - Pain Score at Month 12 Post-Operation

    Participants rate their pain on a scale from 0 (no pain) to 10 (worst pain imaginable); the response is the total score.

    Time frame: Baseline, Month 12 Post-Operation

07

Study locations

1 site
  • NYU Langone Health
    New York, New York 10016, United States
08

References and documents

Individual participant data

Plan to share: No — De-identified participant data will not be available to other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06289153
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Apr 1, 2025 (estimated)
Primary completion
Mar 26, 2026 (estimated)
Completion
Sep 26, 2026 (estimated)
Last update
Jan 9, 2026

Study contacts

Guillem Gonzalez-Lomas, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion